Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Macular Degeneration × CNS × Clear all

Phase

Status

Terminated 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1 Gastrointestinal 1 CNS 1 Breast 1

Conditions

Brain Neoplasms 250 Glioblastoma 223 Glioma 143 Astrocytoma 92 Central Nervous System Neoplasms 67 Gliosarcoma 63 Oligodendroglioma 57 Neuroblastoma 56 Neoplasms 48 Breast Neoplasms 43 Melanoma 39 Carcinoma, Non-Small-Cell Lung 37 Neoplasm Metastasis 30 Lymphoma 28 Recurrence 26 Medulloblastoma 26 Lung Neoplasms 26 Ependymoma 21 Ovarian Neoplasms 19 Lymphoma, Follicular 18 Sarcoma 17 Precursor Cell Lymphoblastic Leukemia-Lymphoma 17 Lymphoma, Non-Hodgkin 17 Leukemia 17 Meningioma 16 Burkitt Lymphoma 16 Multiple Myeloma 15 Meningeal Carcinomatosis 15 Lymphoma, Large B-Cell, Diffuse 15 Carcinoma, Renal Cell 15

Interventions

brolucizumab 1 aflibercept 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡